Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China
Haematologica
.
2022 Aug 1;107(8):1966-1970.
doi: 10.3324/haematol.2022.280637.
Authors
Yilin Chen
1
,
Zelin Liu
2
,
Jing Zou
1
,
Danyu Wang
2
,
Wenjuan He
1
,
Li Meng
3
,
Fanjun Cheng
4
,
Yanli Zhang
5
,
Weiming Li
6
Affiliations
1
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei.
2
Institute of Hematology,Huazhong University of Science and Technology Union Shenzhen Hospital, Guangdong Medical University, Shenzhen, Guangdong.
3
Institute of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei.
4
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei.
[email protected]
.
5
Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan.
[email protected]
.
6
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei.
[email protected]
.
PMID:
35484651
PMCID:
PMC9335083
DOI:
10.3324/haematol.2022.280637
No abstract available
MeSH terms
China
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Protein Kinase Inhibitors / therapeutic use
Retrospective Studies
Substances
Protein Kinase Inhibitors
Imatinib Mesylate